MONDAY, Mar. 2 (HealthDay News) -- Statin use in men is independently associated with a 50 percent or greater reduced risk of death from prostate cancer, according to research presented at the American Society of Clinical Oncology's Genitourinary Cancers Symposium held Feb. 26 to 28 in Orlando.
Stephen Marcella, M.D., of the UMDNJ-School of Public Health in Piscataway, N.J., and a colleague identified all New Jersey men who died from prostate cancer between 1989 and 2001, and matched each man by age and race to a population-based control.
The researchers' unadjusted analysis found that statin exposure was associated with a significantly decreased risk of death from prostate cancer (odds ratio, 0.50). When they adjusted for exposure to any hypertensive medication, they found an even lower risk associated with statin exposure (odds ratio, 0.40). When they adjusted for co-morbid conditions, obesity, and education, they found that statin exposure continued to be associated with a significantly lower risk (odds ratio, 0.40).
"This study adds to the body of evidence linking statin use with a decreased risk for prostate cancer death," the authors conclude.
Abstract
